Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX

The CCP4 suite: programs for protein crystallography

Number Collaborative Computational Project (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,299 · see citing works

Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination

Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse‐Kunstleve, R. W., Jiang, J., Kuszewski, J. J., Nilges, M., Pannu, N., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,720 · see citing works

Improved methods for building protein models in electron density maps and the location of errors in these models

Jones, T. A., Zou, J.-Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,650 · see citing works

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

A solution for the best rotation to relate two sets of vectors

Kabsch, W. (1976) · Acta Crystallographica Section A · doi:10.1107/s0567739476001873 · Cited by 3,462 · see citing works

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works

Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949 · see citing works

The p53-mdm-2 autoregulatory feedback loop.

Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801 · see citing works

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,447 · see citing works

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · see citing works

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · see citing works

Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization

Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245 · see citing works

The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2

Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K. M., Hara, E., Vousden, K. H., et al. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,165 · see citing works

Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency

Kapust, R. B., Tőzsér, J., Fox, J. D., Anderson, D. E., Cherry, S., Copeland, T. D., & Waugh, D. S. (2001) · Protein Engineering Design and Selection · doi:10.1093/protein/14.12.993 · Cited by 860 · see citing works

Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence

Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847 · see citing works

Mapping of the p53 and mdm-2 Interaction Domains

Chen, J., Maréchal, V., & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 689 · see citing works

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · see citing works

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Preprint

Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 652 · see citing works

MDMX: a novel p53‐binding protein with some functional properties of MDM2.

Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648 · see citing works

Divorcing ARF and p53: an unsettled case

Sherr, C. J. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1954 · Cited by 595 · see citing works

Inactivation of the p53 pathway in retinoblastoma

Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595 · see citing works

Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide

Bernal, F., Tyler, A. F., Korsmeyer, S. J., Walensky, L. D., & Verdine, G. L. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0693587 · Cited by 559 · see citing works

Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53

Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517 · see citing works

p53 regulates maternal reproduction through LIF

Hu, W., Feng, Z., Teresky, A. K., & Levine, A. J. (2007) · Nature · doi:10.1038/nature05993 · Cited by 446 · see citing works

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391 · see citing works

Mapping of the p53 and mdm-2 Interaction Domains

Chen, J., Maréchal, V., & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107-4114.1993 · Cited by 247 · see citing works

MDM2 promotes ubiquitination and degradation of MDMX

Pan, Y., & Chen, J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.15.5113-5121.2003 · Cited by 246 · see citing works

MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin

Hu, B., Gilkes, D. M., Farooqi, B., Sebti, S. M., & Chen, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600147200 · Cited by 236 · see citing works

Efficient p53 Activation and Apoptosis by Simultaneous Disruption of Binding to MDM2 and MDMX

Hu, B., Gilkes, D. M., & Chen, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1140 · Cited by 214 · see citing works

Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain

Popowicz, G. M., Czarna, A., & Holak, T. A. (2008) · Cell Cycle · doi:10.4161/cc.6365 · Cited by 195 · see citing works

Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3

Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189 · see citing works

Hdmx modulates the outcome of p53 activation in human tumor cells

Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163 · see citing works

MDMX regulation of p53 response to ribosomal stress

Gilkes, D. M., Chen, L., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601424 · Cited by 142 · see citing works

The central region of HDM2 provides a second binding site for p53

Yu, G. W., Rüdiger, S., Veprintsev, D. B., Freund, S. M. V., Fernández-Fernández, M. R., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510343103 · Cited by 139 · see citing works

Molecular Basis for the Inhibition of p53 by Mdmx

Popowicz, G. M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., & Holak, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4740 · Cited by 131 · see citing works

Structure–Activity Studies in a Family of β‐Hairpin Protein Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction

Fasan, R., Dias, R. L. A., Moehle, K., Zerbe, O., Obrecht, D., Mittl, P. R. E., Grütter, M. G., & Robinson, J. A. (2006) · ChemBioChem · doi:10.1002/cbic.200500452 · Cited by 129 · see citing works

High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx

Czarna, A., Popowicz, G. M., Pęcak, A., Wolf, S., Dubin, G., & Holak, T. A. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8185 · Cited by 99 · see citing works

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation

Xia, M., Knezevic, D., Tovar, C., Huang, B., Heimbrook, D. C., & Vassilev, L. T. (2008) · Cell Cycle · doi:10.4161/cc.7.11.5929 · Cited by 75 · see citing works

Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction

Zhang, R., Mayhood, T., Lipari, P., Wang, Y., Durkin, J., Syto, R., Gesell, J. J., McNemar, C., & Windsor, W. T. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.03.009 · Cited by 75 · see citing works

Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction

ZHANG, R., Mayhood, T., LIPARI, P., Wang, Y., Durkin, J., Syto, R., GESELL, J., McNemar, C., & Windsor, W. T. (2004) · Analytical Biochemistry · doi:10.1016/s0003-2697(04)00223-4 · Cited by 67 · see citing works

BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death

Wade, M., Rodewald, L. W., Espinosa, J. M., & Wahl, G. M. (2008) · Cell Cycle · doi:10.4161/cc.7.13.6072 · Cited by 48 · see citing works

Identification of a disruptor of the MDM2-p53 protein–protein interaction facilitated by high-throughput in silico docking

Lawrence, H. R., Li, Z., Yip, M. L. R., Sung, S., Lawrence, N. J., McLaughlin, M. L., McManus, G. J., Zaworotko, M. J., Sebti, S. M., Chen, J., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.124 · Cited by 29 · see citing works

Cellular senescence and cancer

(1999) · doi:10.1002/(sici)1096-9896(199901)187:1

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 723 · see citing works

Structure‐Based Design of Inhibitors of Protein–Protein Interactions: Mimicking Peptide Binding Epitopes

Pelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412070 · Cited by 718 · see citing works

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Chang, Y. S., Graves, B. J., Guerlavais, V., Tovar, C., Packman, K. E., To, K.-H., Olson, K. A., Kesavan, K. P., Gangurde, P., Mukherjee, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303002110 · Cited by 666 · see citing works

Modulators of Protein–Protein Interactions

Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497 · see citing works

Translating p53 into the clinic

Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · see citing works

Structure of the Stapled p53 Peptide Bound to Mdm2

Baek, S., Kutchukian, P. S., Verdine, G. L., Huber, R., Holak, T. A., Lee, K. W., & Popowicz, G. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2090367 · Cited by 259 · see citing works

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia

Carvajal, L. A., Neriah, D. B., Senecal, A., Benard, L., Thiruthuvanathan, V., Yatsenko, T., Narayanagari, S.-R., Wheat, J. C., Todorova, T. I., Mitchell, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao3003 · Cited by 249 · see citing works

Stapled Peptides with Improved Potency and Specificity That Activate p53

Brown, C. J., Quah, S. T., Jong, J., Goh, A. M., Chiam, P. C., Khoo, K. H., Choong, M. L., Lee, M. A., Yurlova, L., Zolghadr, K., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb3005148 · Cited by 206 · see citing works

Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils

Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 192 · see citing works

The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets Serious

Popowicz, G. M., Dömling, A. S. S., & Holak, T. A. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201003863 · Cited by 166 · see citing works

Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions

Li, C. V., Pazgier, M., Li, C., Yuan, W., Liu, M., Wei, G., Lu, W., & Lu, W. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.005 · Cited by 146 · see citing works

Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development

Guerlavais, V., Sawyer, T. K., Carvajal, L. A., Chang, Y. S., Graves, B. J., Ren, J.-G., Sutton, D., Olson, K. A., Packman, K. E., Darłak, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00623 · Cited by 145 · see citing works

Nitrogen Arylation for Macrocyclization of Unprotected Peptides

Lautrette, G., Touti, F., Lee, H. G., Dai, P., & Pentelute, B. L. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b03757 · Cited by 131 · see citing works

Palladium Oxidative Addition Complexes for Peptide and Protein Cross-linking

Kubota, K., Dai, P., Pentelute, B. L., & Buchwald, S. L. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b00172 · Cited by 129 · see citing works

Double Strain‐Promoted Macrocyclization for the Rapid Selection of Cell‐Active Stapled Peptides

Lau, Y. H., Wu, Y., Rossmann, M., Tan, B. X., de Andrade, P., Tan, Y. S., Verma, C. S., McKenzie, G. J., Venkitaraman, A. R., Hyvönen, M., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201508416 · Cited by 126 · see citing works

Novel Pyrrolopyrimidine-Based α-Helix Mimetics: Cell-Permeable Inhibitors of Protein−Protein Interactions

Lee, J. H., Zhang, Q., Jo, S., Chai, S. C., Oh, M., Im, W., Lu, H., & Lim, H. (2010) · Journal of the American Chemical Society · doi:10.1021/ja108230s · Cited by 126 · see citing works

Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications

Lombardi, L., Genio, V. D., Alberício, F., & Williams, D. R. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00989 · Cited by 126 · see citing works

Divergent unprotected peptide macrocyclisation by palladium-mediated cysteine arylation

Rojas, A. J., Zhang, C., Vinogradova, E. V., Buchwald, N. H., Reilly, J., Pentelute, B. L., & Buchwald, S. L. (2017) · Chemical Science · doi:10.1039/c6sc05454d · Cited by 112 · see citing works

Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition

Madden, M. M., Muppidi, A., Li, Z., Li, X., Chen, J., & Lin, Q. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.004 · Cited by 104 · see citing works

PepCrawler: a fast RRT-based algorithm for high-resolution refinement and binding affinity estimation of peptide inhibitors

Donsky, E., & Wolfson, H. J. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr498 · Cited by 102 · see citing works

Ranking Peptide Binders by Affinity with AlphaFold**

Chang, L., & Perez, A. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202213362 · Cited by 100 · see citing works

How To Design a Successful p53–MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures

Estrada‐Ortiz, N., Neochoritis, C. G., & Dömling, A. S. S. (2015) · ChemMedChem · doi:10.1002/cmdc.201500487 · Cited by 100 · see citing works

Strukturbasierte Entwicklung von Protein‐Protein‐Interaktionsinhibitoren: Stabilisierung und Nachahmung von Peptidliganden

Pelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie · doi:10.1002/ange.201412070 · Cited by 90 · see citing works

Achieving cell penetration with distance-matching cysteine cross-linkers: a facile route to cell-permeable peptide dual inhibitors of Mdm2/Mdmx

Muppidi, A., Wang, Z., Li, X., Chen, J., & Lin, Q. (2011) · Chemical Communications · doi:10.1039/c1cc13320a · Cited by 87 · see citing works

Sulfono-γ-AApeptides as Helical Mimetics: Crystal Structures and Applications

Sang, P., Shi, Y., Huang, B., Xue, S., Odom, T., & Cai, J. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00482 · Cited by 86 · see citing works

Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide

Dougherty, P. G., Wen, J., Pan, X., Koley, A., Ren, J.-G., Sahni, A., Basu, R., Salim, H., Kubi, G. A., Qian, Z., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00456 · Cited by 83 · see citing works

Therapeutic stapled peptides: Efficacy and molecular targets

Li, Y., Wu, M., Fu, Y., Xue, J., Yuan, F., Qu, T., Rissanou, A. N., Wang, Y., Li, X., & Hu, H. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107137 · Cited by 85 · see citing works

In-solution enrichment identifies peptide inhibitors of protein–protein interactions

Touti, F., Gates, Z. P., Bandyopadhyay, A., Lautrette, G., & Pentelute, B. L. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0245-2 · Cited by 81 · see citing works

Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry

Li, C., Pazgier, M., Li, J., Li, C., Liu, M., Zou, G., Li, Z., Chen, J., Tarasov, S. G., Lu, W., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116814 · Cited by 79 · see citing works

Peptidomimetics: A Synthetic Tool for Inhibiting Protein–Protein Interactions in Cancer

Mabonga, L., & Kappo, A. P. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09831-5 · Cited by 78 · see citing works

α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53–MDM2/MDMX Protein–Protein Interactions

Sang, P., Shi, Y., Lu, J., Chen, L., Yang, L., Borcherds, W. M., Abdulkadir, S., Li, Q., Daughdrill, G. W., Chen, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00993 · Cited by 78 · see citing works

Computed Binding of Peptides to Proteins with MELD-Accelerated Molecular Dynamics

Morrone, J. A., Pérez, A., MacCallum, J. L., & Dill, K. A. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6b00977 · Cited by 75 · see citing works

A Natural Small Molecule Harmine Inhibits Angiogenesis and Suppresses Tumour Growth through Activation of p53 in Endothelial Cells

Dai, F., Chen, Y., Song, Y., Huang, L., Zhai, D., Dong, Y., Lai, L., Zhang, T., Li, D., Pang, X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052162 · Cited by 76 · see citing works

A computational analysis of binding modes and conformation changes of MDM2 induced by p53 and inhibitor bindings

Chen, J., Wang, J., Zhu, W., & Li, G. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9693-z · Cited by 75 · see citing works

An α‐Helix‐Mimicking 12,13‐Helix: Designed α/β/γ‐Foldamers as Selective Inhibitors of Protein–Protein Interactions

Grison, C. M., Miles, J. A., Robin, S., Wilson, A. J., & Aitken, D. J. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201604517 · Cited by 75 · see citing works

Regulation of MDM2 E3 Ligase Activity by Phosphorylation after DNA Damage

Cheng, Q., Cross, B. L., Li, B., Chen, L., Li, Z., & Chen, J. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05553-11 · Cited by 73 · see citing works

Ordering of the N-Terminus of Human MDM2 by Small Molecule Inhibitors

Michelsen, K., Jordan, J. B., Lewis, J. K., Long, A. M., Yang, E., Rew, Y., Zhou, J., Yakowec, P. S., Schnier, P. D., Huang, X. Y., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja305839b · Cited by 71 · see citing works

Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73

Zdzalik, M., Pustelny, K., Kędracka–Krok, S., Huben, K., Pęcak, A., Władyka, B., Jankowski, S., Dubin, A., Potempa, J., & Dubin, G. (2010) · Cell Cycle · doi:10.4161/cc.9.22.13871 · Cited by 65 · see citing works

Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression

Chen, S., Li, X., Li, Y., Xing, Y., Geng, C., Gao, S., Li, J., Ma, B., Wang, Z., Lu, W., et al. (2022) · Theranostics · doi:10.7150/thno.75444 · Cited by 64 · see citing works

Computational approaches for the design of modulators targeting protein-protein interactions

Rehman, A. U., Khurshid, B., Ali, Y., Rasheed, S., Wadood, A., Ng, H. L., Chen, H., Wei, Z., Luo, R., & Zhang, J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2171396 · Cited by 62 · see citing works

When the guardian sleeps: Reactivation of the p53 pathway in cancer

Merkel, O., Taylor, N., Prutsch, N., Staber, P. B., Moriggl, R., Turner, S. D., & Kenner, L. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.02.003 · Cited by 54 · see citing works

Molecular Simulations Identify Binding Poses and Approximate Affinities of Stapled α-Helical Peptides to MDM2 and MDMX

Morrone, J. A., Pérez, A., Deng, Q., Ha, S., Holloway, M. K., Sawyer, T. K., Sherborne, B. S., Brown, F. K., & Dill, K. A. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6b00978 · Cited by 54 · see citing works

Using Peptides to Study Protein–Protein Interactions

Benyamini, H., & Friedler, A. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.196 · Cited by 51 · see citing works

Autoinhibition of MDMX by intramolecular p53 mimicry

Chen, L., Borcherds, W. M., Wu, S., Becker, A., Schönbrunn, E., Daughdrill, G. W., & Chen, J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420833112 · Cited by 49 · see citing works

Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation

Chen, J., Wang, J., Zhang, Q., Chen, K., & Zhu, W. (2015) · Scientific Reports · doi:10.1038/srep17421 · Cited by 49 · see citing works

Rational, Computer-Enabled Peptide Drug Design: Principles, Methods, Applications and Future Directions

Diller, D., Swanson, J., Bayden, A. S., Jarosinski, M. A., & Audie, J. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.142 · Cited by 48 · see citing works

Casein Kinase 1α Regulates an MDMX Intramolecular Interaction To Stimulate p53 Binding

Wu, S., Chen, L., Becker, A., Schönbrunn, E., & Chen, J. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00851-12 · Cited by 48 · see citing works

Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein–Protein Interactions

Zhang, S., Lou, J., Li, Y., Zhou, F., Yan, Z., Lyu, X., & Zhao, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00940 · Cited by 47 · see citing works

Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics

Swenson, C., Mandava, G., Thomas, D. M., & Moellering, R. E. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00423 · Cited by 48 · see citing works

Computational Modeling as a Tool to Investigate PPI: From Drug Design to Tissue Engineering

Pérez, J. J., Pérez, R. A., & Pérez, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.681617 · Cited by 43 · see citing works

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression

Li, X., Gohain, N., Chen, S., Li, Y., Zhao, X., Li, B., Tolbert, W. D., He, W., Pazgier, M., Hu, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.010 · Cited by 44 · see citing works

Molecular Basis of Bcl-XL-p53 Interaction: Insights from Molecular Dynamics Simulations

Bharatham, N., Chi, S., & Yoon, H. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026014 · Cited by 40 · see citing works

Directed Evolution Using Stabilized Bacterial Peptide Display

Navaratna, T. A., Atangcho, L., Mahajan, M. K., Vivekanandan, S., Case, M., Min, A., Tresnak, D. T., & Thurber, G. M. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10716 · Cited by 35 · see citing works

New Modalities in Conformationally Constrained Peptides for Potency, Selectivity and Cell Permeation

Dharanipragada, R. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.25 · Cited by 36 · see citing works

Ligand Binding Mode Prediction by Docking: Mdm2/Mdmx Inhibitors as a Case Study

Bharatham, N., Bharatham, K., Shelat, A. A., & Bashford, D. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci4004656 · Cited by 36 · see citing works

Optimal Affinity Enhancement by a Conserved Flexible Linker Controls p53 Mimicry in MdmX

Borcherds, W. M., Becker, A., Chen, L., Chen, J., Chemes, L. B., & Daughdrill, G. W. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.04.017 · Cited by 36 · see citing works

Development of cell‐penetrating peptide‐based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions

Philippe, G. J.-B., Huang, Y., Cheneval, O., Lawrence, N., Zhang, Z., Fairlie, D. P., Craik, D. J., de Araujo, A. D., & Henriques, S. T. (2016) · Biopolymers · doi:10.1002/bip.22893 · Cited by 35 · see citing works

Non-symmetric stapling of native peptides

Chen, F., Lin, W., & Chen, F. (2024) · Nature Reviews Chemistry · doi:10.1038/s41570-024-00591-5 · Cited by 36 · see citing works

Monitoring Ligand-Induced Protein Ordering in Drug Discovery

Grace, C. R., Ban, D., Min, J., Mayasundari, A., Min, L., Finch, K. E., Griffiths, L. M., Bharatham, N., Bashford, D., Guy, R. K., et al. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.01.016 · Cited by 34 · see citing works

Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment

Camps-Fajol, C., Cavero, D., Minguillón, J., & Surrallés, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107544 · Cited by 35 · see citing works

mRNA Display Selection of an Optimized MDM2-Binding Peptide That Potently Inhibits MDM2-p53 Interaction

Shiheido, H., Takashima, H., Doi, N., & Yanagawa, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017898 · Cited by 33 · see citing works

Molecular Dynamic Simulation Insights into the Normal State and Restoration of p53 Function

Fu, T., Min, H., Xu, Y., Chen, J., & Li, G. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089709 · Cited by 32 · see citing works

Artificial Macrocycles as Potent p53–MDM2 Inhibitors

Estrada‐Ortiz, N., Neochoritis, C. G., Twarda‐Clapa, A., Musielak, B., Holak, T. A., & Dömling, A. S. S. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00219 · Cited by 32 · see citing works

Solubility-Aware Protein Binding Peptide Design Using AlphaFold

Kosugi, T., & Ohue, M. (2022) · Biomedicines · doi:10.3390/biomedicines10071626 · Cited by 33 · see citing works

Hitting Undruggable Targets: Viewing Stabilized Peptide Development through the Lens of Quantitative Systems Pharmacology

Atangcho, L., Navaratna, T. A., & Thurber, G. M. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.11.008 · Cited by 31 · see citing works

PinaColada: peptide–inhibitor ant colony ad-hoc design algorithm

Zaidman, D., & Wolfson, H. J. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw133 · Cited by 30 · see citing works

Suprastapled Peptides: Hybridization-Enhanced Peptide Ligation and Enforced α-Helical Conformation for Affinity Selection of Combinatorial Libraries

Sabale, P. M., Imiołek, M., Raia, P., Barluenga, S., & Winssinger, N. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c07013 · Cited by 28 · see citing works

Double Strain‐Promoted Macrocyclization for the Rapid Selection of Cell‐Active Stapled Peptides

Lau, Y. H., Wu, Y., Rossmann, M., Tan, B. X., de Andrade, P., Tan, Y. S., Verma, C. S., McKenzie, G. J., Venkitaraman, A. R., Hyvönen, M., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201508416 · Cited by 29 · see citing works

Overcoming Challenges in the Metabolism of Peptide Therapeutics: Strategies and Case Studies for Clinical Success.

Ma, B., Fuhrmann, J., Henriksen, H. C., Khojasteh, S. C., Li, W., Liu, J., Plise, E., Yu, Q.-Y., & Cheruzel, L. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02276 · Cited by 25 · see citing works

Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents

Mondal, C., Halder, A. K., Adhikari, N., Saha, A., Saha, K. D., Gayen, S., & Jha, T. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.12.011 · Cited by 27 · see citing works

Tuning the Binding Affinity and Selectivity of Perfluoroaryl‐Stapled Peptides by Cysteine‐Editing

Verhoork, S. J. M., Jennings, C., Rozatian, N., Reeks, J., Meng, J., Corlett, E. K., Bunglawala, F., Noble, M. E. M., Leach, A. G., & Coxon, C. R. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201804163 · Cited by 27 · see citing works

MdmX Is Required for p53 Interaction with and Full Induction of the Mdm2 Promoter after Cellular Stress

Biderman, L., Poyurovsky, M. V., Assia, Y., Manley, J. L., & Prives, C. L. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06150-11 · Cited by 26 · see citing works

Calculation of hot spots for protein–protein interaction in p53/PMI‐MDM2/MDMX complexes

Huang, D., Qi, Y., Song, J., & Zhang, J. Z. H. (2018) · Journal of Computational Chemistry · doi:10.1002/jcc.25592 · Cited by 26 · see citing works

Computational Studies of Difference in Binding Modes of Peptide and Non-Peptide Inhibitors to MDM2/MDMX Based on Molecular Dynamics Simulations

Chen, J., Zhang, D., Zhang, Y., & Li, G. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13022176 · Cited by 26 · see citing works

A systems wide mass spectrometric based linear motif screen to identify dominant in-vivo interacting proteins for the ubiquitin ligase MDM2

Nicholson, J., Scherl, A., Way, L., Blackburn, E. A., Walkinshaw, M. D., Ball, K. L., & Hupp, T. R. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.02.011 · Cited by 25 · see citing works

Anticancer strategies by upregulating p53 through inhibition of its ubiquitination by MDM2

Anifowose, A., Agbowuro, A. A., Yang, X., & Wang, B. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02574-9 · Cited by 25 · see citing works

Regulation of MDM4

Markey, M. P. (2010) · Frontiers in bioscience · doi:10.2741/3780 · Cited by 24 · see citing works

Break CDK2/Cyclin E1 Interface Allosterically with Small Peptides

Chen, H., Zhao, Y., Li, H., Zhang, D., Huang, Y., Shen, Q., Duyne, R. V., Kashanchi, F., Zeng, C., & Liu, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109154 · Cited by 23 · see citing works

Peptide Activators of the p53 Tumor Suppressor

Zhan, C., & Lu, W. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222577 · Cited by 23 · see citing works

Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review

Teveroni, E., Lucà, R., Pellegrino, M., Ciolli, G., Pontecorvi, A., & Moretti, F. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1233179 · Cited by 23 · see citing works

Sempervirine inhibits RNA polymerase I transcription independently from p53 in tumor cells

Caggiano, C., Guida, E., Todaro, F., Bielli, P., Mori, M., Ghirga, F., Quaglio, D., Botta, B., Moretti, F., Grimaldi, P., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00345-4 · Cited by 21 · see citing works

Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay

Golestanian, S., Sharifi, A., Popowicz, G. M., Azizian, H., Foroumadi, A., Szwagierczak, A., Holak, T. A., & Amanlou, M. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.12.047 · Cited by 21 · see citing works

Assessing the capability of in silico mutation protocols for predicting the finite temperature conformation of amino acids

Ochoa, R., Soler, M. A., Laio, A., & Cossio, P. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c8cp03826k · Cited by 20 · see citing works

Water-soluble, stable and azide-reactive strained dialkynes for biocompatible double strain-promoted click chemistry

Sharma, K., Strizhak, A. V., Fowler, E., Wang, X., Xu, W., Jensen, C. H., Wu, Y., Sore, H. F., Lau, Y. H., Hyvönen, M., et al. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob01745c · Cited by 20 · see citing works

Insight Into the Binding Mechanism of p53/pDIQ-MDMX/MDM2 With the Interaction Entropy Method

Li, M., Cong, Y., Li, Y., Zhong, S., Wang, R., Li, H., & Duan, L. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00033 · Cited by 20 · see citing works

Structural Basis for Inhibition of the MDM2:p53 Interaction by an Optimized MDM2-Binding Peptide Selected with mRNA Display

Nagata, T., Shirakawa, K., Kobayashi, N., Shiheido, H., Tabata, N., Sakuma-Yonemura, Y., Horisawa, K., Katahira, M., Doi, N., & Yanagawa, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109163 · Cited by 20 · see citing works

Binding Ensembles of p53-MDM2 Peptide Inhibitors by Combining Bayesian Inference and Atomistic Simulations

Lang, L., & Pérez, A. (2021) · Molecules · doi:10.3390/molecules26010198 · Cited by 19 · see citing works

Design and development of high affinity dual anticancer peptide-inhibitors against p53-MDM2/X interaction

Rasafar, N., Barzegar, A., & Aghdam, E. M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117358 · Cited by 19 · see citing works

Simulating Molecular Mechanisms of the MDM2-Mediated Regulatory Interactions: A Conformational Selection Model of the MDM2 Lid Dynamics

Verkhivker, G. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040897 · Cited by 18 · see citing works

An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas

Touqan, N., Diggle, C. P., Verghese, E. T., Perry, S., Horgan, K. J., Merchant, W., Anwar, R., Markham, A. F., Carr, I., & Achuthan, R. (2013) · BMC Clinical Pathology · doi:10.1186/1472-6890-13-32 · Cited by 18 · see citing works

Tau protein binds to the P53 E3 ubiquitin ligase MDM2

Sola, M., Rendon-Angel, A., Martinez, V. R., Sgrignani, J., Magrin, C., Piovesana, E., Cavalli, A., Paganetti, P., & Papin, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-37046-8 · Cited by 17 · see citing works

Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2–p53 interaction

Niu, R., Zheng, Q., Zhang, J., & Zhang, H. (2013) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2013.10.005 · Cited by 17 · see citing works

Accelerating physical simulations of proteins by leveraging external knowledge

Pérez, A., Morrone, J. A., & Dill, K. A. (2017) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1309 · Cited by 17 · see citing works

Discovery of new low-molecular-weight p53–Mdmx disruptors and their anti-cancer activities

Uesato, S., Matsuura, Y., Matsue, S., Sumiyoshi, T., Hirata, Y., Takemoto, S., Kawaratani, Y., Yamai, Y., Ishida, K., Sasaki, T., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.021 · Cited by 17 · see citing works

Functionalized Double Strain-Promoted Stapled Peptides for Inhibiting the p53-MDM2 Interaction

Sharma, K., Strizhak, A. V., Fowler, E., Xu, W., Chappell, B. G. N., Sore, H. F., Galloway, W. R. J. D., Grayson, M. N., Lau, Y. H., Itzhaki, L. S., et al. (2020) · ACS Omega · doi:10.1021/acsomega.9b03459 · Cited by 16 · see citing works

Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction

Rasafar, N., Barzegar, A., & Aghdam, E. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-67510-8 · Cited by 15 · see citing works

p53–MDM2 and MDMX Antagonists

Neochoritis, C. G., Estrada‐Ortiz, N., Khoury, K., & Dömling, A. S. S. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00012-2 · Cited by 16 · see citing works

MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers

Liu, J., Yang, J., Pan, Q., Wang, X., Wang, X., Chen, H., Zheng, X., & Huang, Q. (2024) · European journal of medical research · doi:10.1186/s40001-024-01684-z · Cited by 15 · see citing works

The cis conformation of proline leads to weaker binding of a p53 peptide to MDM2 compared to trans

Zhan, Y. A., & Ytreberg, F. M. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.03.021 · Cited by 15 · see citing works

Live-cell imaging of p53 interactions using a novel Venus-based bimolecular fluorescence complementation system

Amaral, J. D., Herrera, F., Rodrigues, P. M., Dionísio, P. A., Outeiro, T. F., & Rodrigues, C. M. P. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.12.009 · Cited by 15 · see citing works

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391 · see citing works

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression

Li, X., Gohain, N., Chen, S., Li, Y., Zhao, X., Li, B., Tolbert, W. D., He, W., Pazgier, M., Hu, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.010 · Cited by 44 · see citing works

Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction

Rasafar, N., Barzegar, A., & Aghdam, E. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-67510-8 · Cited by 15 · see citing works

Design of a novel MDM2 binding peptide based on the p53 family

Madhumalar, A., Jun, L. H., Brown, C. J., Lane, D. P., & Verma, C. S. (2009) · Cell Cycle · doi:10.4161/cc.8.17.9516 · Cited by 26 · see citing works

De novo design and evaluation of dual inhibitory peptide binders targeting MDMX-p53 and MDM2-p53 interactions

Durojaye, O. A., Bellah, S. F., Uzoeto, H. O., Ezechukwu, S. P., Arazu, A. V., Ajima, J. N., Ngwu, A. N., & Cosmas, S. (2026) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-026-00765-8